Health Care · Biotechnology
Stock price divided by trailing twelve-month (TTM) GAAP earnings per share. Shows how much investors pay for each dollar of recent profit.
Latest P/E Ratio
-14.45x
As of Oct 8, 2026
Beyond P/E Ratio, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | P/E Ratio |
|---|---|
| Oct 8, 2026 | -14.45x |
| Feb 12, 2026 | -4.08x |
| Jan 27, 2026 | -73.91x |
| Mar 5, 2025 | -267.17x |
| Mar 4, 2025 | -267.17x |
| Feb 26, 2025 | -53.43x |
| Feb 19, 2025 | -48.09x |
| Jan 28, 2025 | -40.34x |
P/E Ratio = Current Stock Price ÷ Trailing 12-Month (TTM) Diluted EPS (or Market Cap ÷ TTM Net Income). Chartloom divides stock price by trailing twelve-month EPS, calculated by dividing TTM net income by the weighted-average share count from filings. Note: Variations in share-count conventions across data providers may cause slight differences in reported P/E multiples.
Trailing P/E is based on reported GAAP results and is one of the most widely used valuation metrics.
Read the general P/E Ratio definition, formula, and analyst usage guide.
P/E Ratio guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
Side-by-side comparison